Advertisement
Screener

Quince Therapeutics, Inc. (QNCX) Graph

QNCX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $5.46M; Operating expenses $79.78M; Income tax $75.00K; Net income -$75.49M.
  • 2026-03-31: Research and development $6.84M; Operating expenses $14.59M; Income tax -$5.34M; Net income $35.91M.
  • 2025-12-31: Research and development $12.60M*; Operating expenses $19.35M*; Income tax $3.15M*; Net income (m).
  • 2025-09-30: Research and development $8.08M; Operating expenses $13.43M; Income tax -$46.00K; Net income -$13.44M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$5.46M$79.78M$75.00K-$75.49M
2026-03-31$6.84M$14.59M-$5.34M$35.91M
2025-12-31$12.60M*$19.35M*$3.15M*(m)
2025-09-30$8.08M$13.43M-$46.00K-$13.44M
2025-06-30$6.55M$10.43M$67.00K-$16.05M
2025-03-31$8.14M$14.86M$47.00K-$15.03M
2024-09-30$4.92M$5.86M$13.00K-$5.49M
2024-06-30$4.15M$28.19M$36.00K-$27.73M
2024-03-31$3.70M$11.22M$31.00K-$11.15M
2023-09-30$1.43M$6.09M$0.00-$5.35M
2023-06-30$1.35M$5.58M$0.00-$4.89M
2023-03-31$3.23M$12.96M-$248.00K-$12.25M
2022-09-30$2.45M$7.62M$0.00-$7.92M
2022-06-30$7.20M$16.26M-$284.00K-$16.56M
2022-03-31$12.76M$21.86M$0.00-$21.64M
2021-09-30$14.04M$21.68M$0.00-$21.71M
2021-06-30$14.72M$21.78M$0.00-$21.75M
2021-03-31$16.82M$23.31M(m)-$23.09M
2020-09-30$16.98M$21.91M(m)-$21.51M
2020-06-30$14.09M$18.27M(m)-$17.61M
2020-03-31$14.38M$17.86M(m)-$17.18M
2019-09-30$8.25M$10.57M(m)-$9.86M
2019-06-30$7.11M$9.57M(m)-$9.06M
2019-03-31$4.83M$6.08M(m)-$5.68M
2018-09-30$2.29M$2.87M(m)-$2.52M
2018-06-30$2.29M$2.64M(m)-$3.11M
2018-03-31$2.41M$2.76M(m)-$3.38M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$12.31M$94.37M-$5.26M-$39.58M
2025-06-30$14.70M$25.29M$114.00K-$31.08M
2024-06-30$7.85M$39.41M$67.00K-$38.88M
2023-06-30$4.58M$18.54M-$248.00K-$17.14M
2022-06-30$19.96M$38.08M-$284.00K-$38.20M
2021-06-30$31.54M$45.10M$0.00-$44.84M
2020-06-30$28.47M$36.13M(m)-$34.79M
2019-06-30$11.93M$15.65M(m)-$14.74M
2018-06-30$4.70M$5.40M(m)-$6.49M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$22.78M$38.72M$68.00K-$44.52M
2024-09-30$12.77M$45.27M$80.00K-$44.37M
2023-09-30$6.01M$24.70M-$248.00K-$22.49M
2022-09-30$22.41M$45.70M-$284.00K-$46.13M
2021-09-30$45.58M$66.77M$0.00-$66.55M
2020-09-30$45.45M$58.04M(m)-$56.29M
2019-09-30$20.19M$26.22M(m)-$24.60M
2018-09-30$6.99M$8.28M(m)-$9.01M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$35.38M$58.07M$3.21M-$83.98M
2024-12-31$18.59M$57.28M$87.00K-$56.83M
2023-12-31$9.45M$34.62M-$197.00K-$31.39M
2022-12-31$25.18M$52.02M-$284.00K-$51.66M
2021-12-31$60.80M$90.32M$0.00-$89.94M
2020-12-31$61.31M$78.89M$0.00-$76.85M
2019-12-31$30.21M$39.17M$0.00-$36.98M
2018-12-31$10.09M$12.12M$0.00-$12.48M

Similar stocks

Stock NameCountryMarket CapPE Ratio
CEL SCI CORP (CVM)United States$0.030B-0.81
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Estrella Immunopharma, Inc. (ESLA)United States$0.020B
Scilex Holding Co (SCLX)United States$0.042B-0.14
Jasper Therapeutics, Inc. (JSPR)United States$0.020B-0.37
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioCardia, Inc. (BCDA)United States$0.016B
DYADIC INTERNATIONAL INC (DYAI)United States$0.016B
Passage BIO, Inc. (PASG)United States$0.015B-0.43
LeonaBio, Inc. (LONA)United States$0.047B-0.61